Identification of cancer targets and therapeutics using phage display

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 3, 2006, Pages 363-369

  Brissette, Renee ^a   Prendergast, John K A ^a   Goldstein, Neil I ^a  

^a Antyra Inc   (United States)

Author keywords

Antibodies; Cancer; Peptides; Phage display; Targeted therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER ANTIBODY; CANCER VACCINE; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GALECTIN 3; GEFITINIB; HEMATIDE; MELANOMA ANTIGEN 1; MONOCLONAL ANTIBODY; PEPTIDE; PLEXIN; PROTEIN TYROSINE KINASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOMATOMEDIN; TRASTUZUMAB;

ANEMIA; BACTERIOPHAGE; CANCER PREVENTION; CANCER THERAPY; CLINICAL TRIAL; DNA SEQUENCE; DRUG BINDING; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; NASOPHARYNX CARCINOMA; NONHUMAN; PHAGE DISPLAY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIOPHAGES; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE LIBRARY;

EID: 33646839479     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Smith GP: Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science (1985) 228(4705):1315-1317. One of the first papers discussing phage-display technology.
2. Smith GP, Schultz DA, Ladbury JE: A ribonuclease S-peptide antagonist discovered with a bacteriophage display library. Gene (1993) 128(1):37-42.
3. Cwirla SE, Peters EA, Barrett, RW, Dower WJ: Peptides on phage: A vast library of peptides for identifying ligands. Proc Natl Acad Sci USA (1990) 87(16):6378-6382.
4. Danner S, Belasco JG: T7 phage display: A novel genetic selection system for cloning RNA-binding proteins form cDNA libraries. Proc Natl Acad Sci USA (2001) 98(23):12954-12959. Describes the use of a non-M13 approach to phage display.
5. Minenkova O, Pucci A, Pavoni E, De Tomassi A, Fortugno P, Gargano N, Cianfriglia M, Barca S, De Placido S, Martignetti A, Felici F et al: Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer (2003) 106(4):534-544.
6. Ruoslahti E, Rajotte D: An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol (2000) 18:813-827. Provides a review of in vivo display for identifying organ-specific and tumor-specific peptides.
7. Pillutla RC, Hsiao KC, Beasley JR, Brandt J, Ostergaard S, Hansen PH, Spetzler JC, Danielsen GM, Andersen AS, Brissette RE, Lennick M et al: Peptides identify the critical hotspots involved in the biological activation of the insulin receptor. J Biol Chem (2002) 277(25)22590-22594. Describes the use of bioactive peptides to identify subdomains within the insulin receptor having different pharmacological activity.
8. Hawkins RE, Russell SJ, Winter G: Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol (1992) 226(3):889-896.
9. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwirla SE, Peters-Bhatt E, Whitehorn EA, Tate EH et al: High affinity type I interleukln 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc Natl Acad Sci USA (1996) 93(14):7381-7386.
10. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ: Small peptides as potent mimetics of the protein hormone erythropoietin. Science (1996) 273(5274):458-463.
11. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstron CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos C.M, Schatz PJ et al: Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science (1997) 276(5319):1696-1699.
12. Schaffer L, Brissette RE, Spetzler JC, Pillutla RC, Ostergaard S, Lennick M, Brandt J, Fletcher PW, Danielsen GM, Hsiao KC, Andersen AS et al: Assembly of high affinity insulin receptor agonists and antagonists from peptide building blocks. Proc Natl Acad Sci USA (2003) 100(8):4435-4439. Describes the use of peptides binding to individual subdomains on the insulin receptor to generate a potent insulin mimetic.
13. Pillutla RC, Hsiao K, Brissette R, Eder PS, Giordano T, Fletcher PW, Lennick M, Blume AJ, Goldstein NI: A surrogate-based approach for post-genomic partner identification. BMC Biotechnol (2001) 1:6. doi:10.1186/1472-6750-1-6
14. Blume AJ, Beasley J, Goldstein NI: The use of peptides in diogenesis: A novel approach to drug discovery and phenomics. Biopolymers (2000) 55(4):347-356.
15. Zozulya S, Lioubin M, Hill RJ, Abram C, Gishizky M: Mapping signal transduction pathways by phage display. Nat Biotechnol (1999) 17(12):1193-1198.
16. Tong AH, Drees B, Nardelli G, Bader GD, Brannetti B, Castagnoli L, Evangelists M, Ferracuti S, Nelson B, Paoluzi S, Quondam M et al: A combined experimental strategy to define protein interaction networks for peptide recognition modules. Science (2002) 295(5553):321-324.
17. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, Casal JI: Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res (2005) 11(17):6280-6290.
18. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X et al: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits tumor growth in vivo. Cancer Res (2003) 63(24):8912-8921.
19. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D et al: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem (2005) 280(20):19665-19672. Describes the generation of a bispecific antibody built from individual antibody fragments identified by phage display. The resulting engineered antibody binds to two important receptor tyrosine kinases upregulated in cancer and has improved biological activity in vivo.
20. Lu D, Jimenez X, Witte L, Zhu Z: The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun (2004) 318(2):507-513.
21. Shin I, Edl J, Biswas S, Lin PC, Mernaugh R, Arteaga CL: Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res (2005) 65(7):2815-2824.
22. Roodnick I, Raats J, van der Zwaag B, Verrijp K, Kusters B, van Bokhoven H, Linkels M, de Waal RM, Leenders WP: Plexin D1 expression is induced on tumor vasculature and tumor cells: A novel target for diagnosis and therapy? Cancer Res (2005) 65:8317-8323.
23. Mutuberria R, Satijn S, Huijbers A, van der Linden E, Lichtenbeld H, Chames P, Arends JW, Hoogenboom HR: Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro endothelial cell selection with phage display libraries. J Immunol Methods (2004) 287(1-2):31-47.
24. Binz HK, Amstutz P, Pluckthun A: Engineering novel binding proteins from nonimmunological domains. Nat Biotechnol (2005) 23(10):1257-1268. Provides a review of novel scaffolds for the generation of antibody-like reagents.
25. Silverman J, Lu Q, Bakker A, To W, Duguay A, Alba BM, Smith R, Rivas A, Li P, Le H, Whitehorn E et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol (2005) 23(12):1556-1561. Provides an interesting description of the development of a novel scaffold for generating antibody-like molecules through phage display.
26. Hematide™: Affymax Inc, Palo Alto, CA, USA (2006). http://www. affymax.com/pipeline_hematide.html
27. An P, Lei H, Zhang J, Song S, He L, Jin G, Liu X, Wu J, Meng L, Liu M, Shou C: Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified by phage display. Int J Cancer (2004) 111(2):165-173. Demonstrates that a VEGFR-1-antagonizing peptide identified by phage display inhibited tumor growth and lung metastases in animal models.
28. Zou J, Glinsky W, Landon LA, Matthews L, Deutscher SL: Peptides specific to the galectin-3 carbohydrate recognition domain inhibits metastasis-associated cancer cell adhesion. Carcinogenesis (2005) 26(2):309-318.
29. Pero SC, Shukla GS, Armstrong AL, Peterson D, Fuller SP, Godin K, Kingsley-Richards SL, Weaver DL, Bond J, Krag DN: Identification of a small peptide that inhibits the phosphorylatlon of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int J Cancer (2004) 111(6):951-960.
30. Pasqualini R, Ruoslahti E: Organ targeting in vivo using phage display peptide libraries. Nature (1996) 380(6572):364-366.
31. Ruoslahti E: Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans (2004) 32(Pt3):397-402.
32. Rafii S, Avecilla ST, Jin DK: Tumor vasculature address book: Identification of stage-specific tumor vessel zip codes by phage display. Cancer Cell (2003) 4(5):331-333. Provides a review of the use of in vivo display.
33. Hoffman JA, Giraudo E, Singh M, Zhang L, Inoue M, Porkka K, Hanahan D, Ruoslahti E: Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell (2004) 4(5):383-391.
34. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D: Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2003) 4(5):393-403.
35. Kolonin MG, Bover L, Sun J, Zurita AJ, Do K-A, Lahdenranta J, Cardo-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res (2006) 66(1):34-40. Peptide display was used to identify tripeptide motifs, which were then used to profile cell surface targets expressed on human cancer cell lines.
36. Bockmann M, Hilken G, Schmidt A, Cranston AN, Tannapfel A, Drosten M, Frilling A, Ponder BA, Putzer BM: Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection. Hum Gene Ther (2005) 16(11):1267-1275.
37. Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, Santos A, Silva R, Acevedo B, Lopez E, Falcon V et al: Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res (2004) 64(19):7127-7129.
38. Lee T-Y, WU H-C, Tseng Y-L, Lin C-T: A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res (2004) 64(21):8002-8008. Describes results indicating that a peptide specific for nasopharyngeal carcinoma could be used to deliver doxorubicin to tumors in vivo.
39. Hardy B, Raiter A: A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody. Vaccine (2005) 23(34):4283-4291.
40. Jiang B, Liu W, Qu H, Meng L, Song S, Ouyang T, Shou C: A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2. J Biol Chem (2005) 280(6):4656-4662. A study that identified a 12mer peptide binding to an anti-HER2 antibody, which mimicked a conformational epitope on HER2. Both a humoral and cellular response to HER2 was observed following injection of the peptide into immunocompetent mice.
41. Forster-Waldl E, Riemer AB, Dehof AK, Neumann D, Bramswig K, Boltz-Nitulescu G, Pehamberger H, Zielinski CC, Scheiner O, Pollak A, Lode H et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioiside GD2, a neuroblastoma tumor antigen. Mol Immunol (2005) 42(3):319-325.
42. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E: Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst (2005) 97(22):1663-1670.
43. Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S: Differential immunogenicity of two peptides isolated by high molecular weight-melanoma- associated antigen-specific monoclonal antibodies with different affinities. J Immunol (2005) 174(11):7104-7110.
44. Oyama T, Sykes KF, Samli KN, Minna JD, Johnston SA, Brown KC: Isolation of lung tumor specific peptide library: Generation of diagnostic and cell-targeting reagents. Cancer Lett (2003) 202(2):219-230.
45. Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Kramer S, Altmann A, Eisenhut M, Haberkom U: A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res (2005) 11(1):139-146.